Poll|Articles|September 1, 2023

POLL: Do You Diagnose and Treat Psoriasis Through Telehealth Appointments?

Listen

0:00 / 0:00

Key Takeaways

Telehealth usage in hospitals increased significantly from 2010 to 2017, with further growth expected post-pandemic.
The COVID-19 pandemic accelerated telehealth integration, enhancing access to healthcare services.
Telehealth facilitates the diagnosis and treatment of conditions such as psoriasis, improving patient care delivery.
The American Hospital Association supports telehealth's role in connecting patients to essential healthcare services.

Click here to answer this week’s poll.

Do you diagnose and treat psoriasis through telehealth appointments?

The use of telehealth in hospitals grew from 35% in 2010 to 76% in 2017¹, and since the COVID-19 pandemic, that number has likely increased. Do you diagnose and/or treat psoriasis through telehealth appointments?

Reference

Fact Sheet: Telehealth. American Hospital Association. Accessed August 24, 2023. https://www.aha.org/factsheet/telehealth#:~:text=Telehealth%20connects%20patients%20to%20vital,place%2C%20at%20the%20right%20time

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related to this article

October 30th, 2026

FDA Approves Tildrakizumab for Active Psoriatic Arthritis

The approval expands the IL-23 inhibitor’s indications beyond moderate-to-severe plaque psoriasis to include adults with active psoriatic arthritis.

October 27th, 2026

FDA Revises TB Evaluation Guidance for SKYRIZI

Updated SKYRIZI labeling allows clinicians to use clinical judgment when determining the need for TB evaluation before treatment.

October 27th, 2026

Avoiding Common Mistakes When Escalating Therapy in Psoriasis

Experts outline how to recognize undertreated psoriasis, assess incomplete response, and make individualized decisions when escalating therapy.

October 26th, 2026

ORKA-001 Achieves 61% Complete Skin Clearance in Psoriasis

ORKA-001 achieved PASI 100 in 61% of high-dose patients at week 16 in the phase 2b EVERLAST-B trial of moderate-to-severe psoriasis.

October 21st, 2026

Nonsteroidal Topicals Guide Special-Site Psoriasis Treatment Decisions

Tina Bhutani-Jacques, MD, explored how disease location, prior treatment response, and patient preference shape topical treatment decisions across 3 plaque psoriasis cases.

October 20th, 2026

Fall Clinical 2026: The Data and Expert Advice Shaping Dermatology Practice

Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.